Talk:Clozapine

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Template:Proofread

Chemical Nomenclature

Common names

Clozaril, FazaClo

Substitutive name

Clozapine

Systematic name

8-Chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine

Class Membership

Psychoactive class

Antipsychotic

Chemical class

Dibenzodiazepine

Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

⇣ Oral
Dosage
Threshold	6.125 mg
Light	12.5 - 25 mg
Common	37.5 - 50 mg
Strong	50 - 100 mg
Heavy	100 mg +
Duration
Total	- hours
Onset	- minutes

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Summary sheet: Clozapine

Clozapine (trade name Clozaril) is an antipsychotic medication that is used to treat severe schizophrenia. However, it only applies to those that have not responded to other medications (studies demonstrated that clozapine was more effective against treatment-resistant schizophrenia than other antipsychotics). Clozapine may also be used to help reduce the risk of suicidal tendencies in people with schizophrenia or similar disorders (Delirium, bipolar disorder, extreme cases of anxiety). Clozapine was first synthesized in 1958 by Wander AG, a Swiss pharmaceutical company, based on the chemical structure of the tricyclic antidepressant imipramine.

Chemistry

A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Year introduced: 1991(1975)